250 related articles for article (PubMed ID: 25976565)
21. Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker.
van der Weerd NC; Grooteman MP; Nubé MJ; ter Wee PM; Swinkels DW; Gaillard CA
Neth J Med; 2015 Mar; 73(3):108-18. PubMed ID: 25852110
[TBL] [Abstract][Full Text] [Related]
22. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
[TBL] [Abstract][Full Text] [Related]
23. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease.
Łukaszyk E; Łukaszyk M; Koc-Żórawska E; Tobolczyk J; Bodzenta-Łukaszyk A; Małyszko J
Kidney Blood Press Res; 2015; 40(4):366-73. PubMed ID: 26160488
[TBL] [Abstract][Full Text] [Related]
24. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis.
Arnold J; Sangwaiya A; Bhatkal B; Geoghegan F; Busbridge M
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):425-9. PubMed ID: 19262400
[TBL] [Abstract][Full Text] [Related]
25. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
[TBL] [Abstract][Full Text] [Related]
26. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease.
Niihata K; Tomosugi N; Uehata T; Shoji T; Mitsumoto K; Shimizu M; Kawabata H; Sakaguchi Y; Suzuki A; Hayashi T; Okada N; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Dec; 27(12):4378-85; discussion 4384-5. PubMed ID: 22833619
[TBL] [Abstract][Full Text] [Related]
27. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients.
Lukaszyk E; Lukaszyk M; Koc-Zorawska E; Bodzenta-Lukaszyk A; Malyszko J
Int Urol Nephrol; 2016 Jun; 48(6):839-44. PubMed ID: 27043030
[TBL] [Abstract][Full Text] [Related]
28. Iron status in patients with chronic heart failure.
Jankowska EA; Malyszko J; Ardehali H; Koc-Zorawska E; Banasiak W; von Haehling S; Macdougall IC; Weiss G; McMurray JJ; Anker SD; Gheorghiade M; Ponikowski P
Eur Heart J; 2013 Mar; 34(11):827-34. PubMed ID: 23178646
[TBL] [Abstract][Full Text] [Related]
29. Hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease.
Min HK; Sung SA; Oh YK; Kim YH; Chung W; Park SK; Ahn C; Lee SW
Nephrol Dial Transplant; 2020 Jan; 35(1):147-154. PubMed ID: 30053139
[TBL] [Abstract][Full Text] [Related]
30. Hepcidin and iron metabolism disorders in patients with chronic kidney disease.
Jelić M; Cvetković T; Djordjević V; Damnjanovć G; Vlahović P; Kocić G; Djindjić N; Jovović B; Antić A
Vojnosanit Pregl; 2013 Apr; 70(4):368-73. PubMed ID: 23700940
[TBL] [Abstract][Full Text] [Related]
31. GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease.
Farag NM; Mousa M; Elsayed E; Ismeil A
Ital J Pediatr; 2023 Aug; 49(1):106. PubMed ID: 37649102
[TBL] [Abstract][Full Text] [Related]
32. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease.
Samouilidou E; Pantelias K; Petras D; Tsirpanlis G; Bakirtzi J; Chatzivasileiou G; Tzanatos H; Grapsa E
Ther Apher Dial; 2014 Jun; 18(3):279-83. PubMed ID: 24119290
[TBL] [Abstract][Full Text] [Related]
33. Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia.
Jacober ML; Mamoni RL; Lima CS; Dos Anjos BL; Grotto HZ
Med Oncol; 2007; 24(3):323-9. PubMed ID: 17873309
[TBL] [Abstract][Full Text] [Related]
34. [Pro-hepcidin, its relation with indicators of iron metabolism and of inflammation in patients hemodialyzed treated or not with recombinant erythropoietin].
Barrios Y; Espinoza M; Barón MA
Nutr Hosp; 2010; 25(4):555-60. PubMed ID: 20694291
[TBL] [Abstract][Full Text] [Related]
35. Adolescent life-event stress in boys is associated with elevated IL-6 and hepcidin but not hypoferremia.
Augustine LF; Nair KM; Rao SF; Rao MV; Ravinder P; Balakrishna N; Laxmaiah A; Vazir S
J Am Coll Nutr; 2014; 33(5):354-62. PubMed ID: 25302670
[TBL] [Abstract][Full Text] [Related]
36. Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection.
de Mast Q; van Dongen-Lases EC; Swinkels DW; Nieman AE; Roestenberg M; Druilhe P; Arens TA; Luty AJ; Hermsen CC; Sauerwein RW; van der Ven AJ
Br J Haematol; 2009 Jun; 145(5):657-64. PubMed ID: 19344417
[TBL] [Abstract][Full Text] [Related]
37. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease.
Basseri RJ; Nemeth E; Vassilaki ME; Basseri B; Enayati P; Shaye O; Bourikas LA; Ganz T; Papadakis KA
J Crohns Colitis; 2013 Sep; 7(8):e286-91. PubMed ID: 23219355
[TBL] [Abstract][Full Text] [Related]
38. A 3-marker index improves the identification of iron disorders in CKD anaemia.
Mercadal L; Metzger M; Haymann JP; Thervet E; Boffa JJ; Flamant M; Vrtovsnik F; Gauci C; Froissart M; Stengel B;
PLoS One; 2014; 9(2):e84144. PubMed ID: 24586229
[TBL] [Abstract][Full Text] [Related]
39. Serum hepcidin levels are related to serum markers for iron metabolism and fibrosis stage in patients with chronic hepatitis B: A cross-sectional study.
Çam H; Yılmaz N
Arab J Gastroenterol; 2020 Jun; 21(2):85-90. PubMed ID: 32423859
[TBL] [Abstract][Full Text] [Related]
40. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
